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Abstract
An accurate diagnosis of clinically distinct subgroups of aggressive mature B cell lymphomas is crucial for the choice of proper
treatment. Presently, precise recognition of these disorders relies on the combination of morphological, immunophenotypical,
and cytogenetic/molecular features. The diagnostic workup in such situations implies the application of costly and time-
consuming analyses, which are not always required, since an intensified treatment option is reasonably reserved to fit patients.
The Italian Group of Haematopathology proposes herein a practical algorithm for the diagnosis of aggressive mature B cell
lymphomas based on a stepwise approach, aimed to select cases deserving molecular analysis, in order to optimize time and
resources still assuring the optimal management for any patient.
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Introduction
Diffuse large B cell lymphomas not otherwise specified
(DLBCL NOS) represent a spectrum of malignancies associ-
ated with diversified clinical outcomes. Characterization of
molecular features of clinical importance, such as the cell of
origin (COO) and the rearrangements of MYC, BCL2, and
BCL6 genes, has been incorporated as a new requirement in
the revised World Health Organization (WHO) classification
of tumors of hematopoietic and lymphoid tissues [1].
Gene expression profiling (GEP) or surrogated immu-
nohistochemical algorithms allow subclassification of
DLBCL NOS mainly into the germinal center (GCB)
and the activated (ABC) or non-GCB types based on
the cell of origin, with ABC lymphomas displaying
poorer prognosis than GCB ones [2]. pt?>Fluorescence
in situ hybridization (FISH) is required to distinguish
among high-grade B cell lymphomas with double or
triple hit rearrangement (HGBL DH/TH), high-grade B
cell lymphomas not otherwise specified (HGBL NOS),
and DLBCL NOS. HGBL DH/TH are aggressive mature
B cell lymphomas with variable morphology, ranging
from pleomorphic large cells to medium-sized cells with
features intermediate between DLBCL and Burkitt lym-
phoma (BCLU), to blastoid cells (Fig. 1), where FISH
analyses identify MYC gene rearrangement in association
with BCL2 and/or BCL6 gene rearrangements (Fig. 2).
Notably, HGBL DH/TH account for approximately 5%
of all cases with DLBCL morphology and generally
have a low complete response rate with R-CHOP that
advises for more intensive chemotherapy regimens [1, 3].
HGBL NOS includes cases with neoplastic B cells hav-
ing either blastoid morphology or histopathological fea-
tures intermediate between DLBCL and Burkitt
Lymphoma (BCLU) that do not carry a double or a
triple rearrangement. Recently, gene expression signatures
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and mutational profiles identified high-risk patients with
DLBCL comprising double hit lymphomas [4].
GEP and FISH studies, which are the elective tech-
nologies for the definition of the COO, of gene rear-
rangements and of high-risk lymphomas are expensive,
time consuming, and not available in all laboratories. To
date, no guidelines are available driving both patholo-
gists and clinicians in the selection of aggressive mature
B cell lymphomas deserving molecular analyses in a
cost-effective management of the patients. The use of
immunohistochemistry, cheaper and widely applicable,
as surrogate tool for the assessment of the COO and
the presence of MYC gene rearrangements in DLBCLs
have been proposed [5–8]. However, this approach bears
intrinsic limitations. Although HGBL-DH overexpress
MYC and BCL2 proteins in most instances, they only
account for a small proportion of the so-called double
expressors DLBCL (DE DLBCL). In addition, HGBL
carrying MYC and BCL2 gene rearrangements almost
exclusively belong to the GCB category, while the ma-
jority of DE DLBCL fall into the non-GCB group [3,
8]. Of note, nearly 20% of GCB DLBCL carrying MYC
rearrangement do not express MYC protein [8].
On the other hand, molecular subtyping all DLBCLs to
identify all HGBL DH/TH may be unnecessary, since treat-
ment choice is also driven by patient’s age, comorbidities, and
performance status, with dose-intense treatment options being
usually reserved to fit and young (age < 60 years) patients.
The purpose of this article is to propose a stepwise, work-
ing algorithm aimed at the rationalization of the diagnostic
efforts in aggressive mature B cell lymphomas. The attempt
is to provide minimal required criteria to select cases deserv-
ing FISH analysis, in order to save time and resources still
assuring the optimal management for any patient.
Fig. 1 Morphological features of aggressive mature B cell lymphomas.
In DLBCL, the cells are pleomorphic with centroblastic and/or
immunoblastic features. Blastoid cells are medium-sized cells with a
fine chromatin pattern and inconspicuous nucleoli. Cases with features
overlapping between BL and DLBCL (BCLU) showmedium-sized cells,
less monomorphic than in classical BL, with multiple paracentrally
located nucleoli and frequent starry sky pattern
Fig. 2 Interphase FISH showing rearrangements ofMYC, BCL2, and BCL6 genes using dual color break-apart (BA) probes.MYC/IGH translocation is
detected using a dual color dual fusion FISH probe
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Sample requirements
This diagnostic workflow applies to any nodal/extranodal,
aggressive mature B cell lymphoma that does not fulfill the
diagnostic criteria of any specific DLBCL entity (e.g., EBV+
DLBCL, primary mediastinal B cell lymphoma, primary cen-
tral nervous systemDLBCL, Tcell histiocyte-rich DLBCL) as
recommended by the revised version of the World Health
Organization classification of lymphoid malignancies.
In order to enable all the required immunohistochemical
and molecular analyses and avoid pre-analytical biases, sam-
ples should contain an adequate amount of tissue embedded in
paraffin within 24 h of formalin fixation. Since core needle
biopsies might not be fully informative to render an accurate
diagnosis of lymphoma, excisional lymph node biopsies
should be favored whenever possible.
Diagnostic workflow
An initial diagnosis of an aggressive mature B cell lym-
phoma should incorporate the assessment of cytological
and immunohistochemical features, including the COO,
and the percentage of MYC- and BCL2-expressing cells.
Whenever a B cell lymphoma with a DLBCL morphology
displays either a GCB COO and/or a double expression of
MYC and BCL2 proteins (in more than 40% and 50% of
neoplastic cells, respectively) (DE DLBCL), analysis of
MYC, BCL2, and BCL6 gene rearrangements by FISH is
indicated in order to rule out the possibility of a HGBL
DH/TH. Although there is no complete agreement about
the percentage of MYC protein-expressing cells that accu-
rately predicts the presence ofMYC gene rearrangement [6,
9, 10], the cutoff value of 70% has been recently reported
to be reproducible among different centers and of clinical
value in identifying patients with a worse prognosis [7].
Before proceeding with FISH analysis, in DLBCL cases, it
is highly recommended to discuss upfront with the referring
hematologist the results of immunohistochemical screening in
order to verify patient’s fitness and potential eligibility to un-
dergo intensified therapy for HGBL DH/TH.
On the contrary, FISH analyses should be performed in any
case of:
a. B cell lymphomas with blastoid morphology, with the
exclusion of TdT+ lymphoblastic lymphoma or cyclin
D1+ pleomorphic/blastoid mantle cell lymphoma
(Fig. 3). In these cases, FISH analysis for MYC, BCL2,
and BCL6 genes allows classification of the malignancy
as HGBL DH/TH or HGBL NOS. CCDN1 translocations
should also be investigated to rule out cyclin D1-
expressing DLBCL.
b. B cell lymphomas with morphological features interme-
diate between DLBCL and Burkitt lymphoma (BCLU).
In these cases, independently of the immunophenotype
exhibited by tumor cells, MYC, BCL2, and BCL6 rear-
rangements should be investigated for the differential di-
agnosis among HGBL DH/TH, HGBL NOS, and Burkitt
lymphoma (Fig. 3). In cases without MYC translocation,
FISH analysis for chromosome 11q is required to identify
Burkitt-like lymphomas with 11q aberrations.
Immunohistochemistry
Aggressive mature B cell lymphomas should express B
cell–associated antigens (e.g., CD20, CD19, CD79a) and
lack cyclin D1. In the case of a cyclin D1+ large B cell
lymphoma, immunohistochemistry for CD5, SOX11, and
FISH analysis with a CCND1 break-apart probe must be
performed in order to rule out a pleomorphic/blastoid
mantle cell lymphoma [1]. The use of CD5 is also en-
couraged to identify de novo CD5+ DLBCLs, which
might display an unfavorable outcome [11].
The COO of DLBCL can be investigated by gene
expression profiling (GEP) or, alternatively, by immuno-
histochemistry (IHC) following algorithms suggested by
the 2017 WHO Classification [1]. Among these, the
most popular is Hans algorithm, which splits DLBCLs
in germinal center (GCB) and non-germinal center (non-
GCB) type based on the expression of CD10, BCL6,
and IRF4/MUM1 proteins [12]. Its output shows reason-
able correlation with the GEP, although some cases of
DLBCL GCB type are misclassified as non-GCB type
by IHC [5]. In addition to its role in discriminating
different DLBCL prognostic subgroups (non-GCB carry-
ing worse prognosis in comparison with GCB type),
determination of COO might help in identifying those
cases potentially harboring rearrangements of MYC,
BCL2, and BCL6. Indeed, almost all the HGBL DH/
TH fall within the GCB subtype with less than 1% of
ABC harboring MYC and BCL2 and 2% MYC and
BCL6 rearrangements [3].
Immunohistochemical investigation of MYC and
BCL2 protein expression in DLBCL is highly recom-
mended since overexpression of these proteins is asso-
ciated with shorter survival [10, 13, 14]. Moreover,
HGBL DH without MYC or BCL2 overexpression dis-
play a more favorable outcome than double expressor
HGBL DH [7, 10, 13, 14]. Cutoff values for MYC
and BCL2 that have been significantly associated with
survival are 40% and 50%, respectively (independently
of the intensity of the staining) [9]. Whenever the IHC
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staining is not homogeneously distributed across the
section, the percentage of positive cells should be cal-
culated as the average, and the occurrence of hot spots
with MYC > 70% should be reported. A high percentage
of MYC+ cells is more likely to be associated with
MYC translocation [6, 7, 9]. Some pathologists have
advocated the use of Ki67 staining, although the prolif-
erative fraction is variable in HGBL DH/TH and it can-
not be considered a reliable marker for screening pa-
tients that require FISH [1, 10].
FISH analysis
Rearrangements of MYC, BCL2, and BCL6 genes are gen-
erally assessed using break-apart probes. Since the definition
of HGBL DH/TH requires the presence of MYC rearrange-
ment, this could be investigated first, followed by BCL2 and
BCL6 gene analyses in MYC rearranged cases. The use of
dual color dual fusion IGH-MYC probes in addition to MYC
break-apart probes (Fig. 2) increases the sensitivity of detec-
tion [14]. Furthermore, the definition of the partner gene
(IGH or non-IGH) of MYC translocation could be clinically
relevant, although this issue is still debated [9, 14, 15]. By
an administrative standpoint, FISH analysis could be request-
ed as an additional investigation either by the clinician or by
the pathologist according to local rules.
Concluding remarks
In conclusion, we believe that the application of the proposed
workflow could represent a useful strategy to rationalize the
procedures and optimize the resources, speeding up the diag-
nosis of aggressivemature B cell lymphomas and allowing the
more appropriate treatment option for each patient.
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